Cancer survivors may experience anxiety over minor illnesses, fearing recurrence despite being in remission. The "positivity trap" can make survivors feel invalidated, as constant reassurance may ...
SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses the growing view that follicular lymphoma could be viewed as ...
"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...
Monjuvi, combined with Rituxan and Revlimid, extends progression-free survival to 22 months, reducing disease progression risk by over 50%. The inMIND trial's design and diverse patient population ...
Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...
An endocrinologist explains the five main types, how they behave, treatment options, and why knowing the exact type can reduce fear and improve outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results